Generic placeholder image

Current Psychiatry Reviews

Editor-in-Chief

ISSN (Print): 1573-4005
ISSN (Online): 1875-6441

Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers

Author(s): Jess G. Fiedorowicz, Del D. Miller, Jeffrey R. Bishop, Chadi A. Calarge, Vicki L. Ellingrod and William G. Haynes

Volume 8 , Issue 1 , 2012

Page: [25 - 36] Pages: 12

DOI: 10.2174/157340012798994867

Price: $65

Abstract

Pharmacological treatments for serious mental illness (SMI) can cause weight gain and adverse metabolic effects. Many second generation antipsychotics and mood stabilizers appear to be particularly problematic in this regard. Several studies have investigated interventions for antipsychotic-induced, or less commonly mood stabilizer-induced, weight gain. Both lifestyle and pharmacological interventions have demonstrated effectiveness. We systematically review randomized controlled trials of pharmacological interventions for weight gain related to these medications. We conducted a meta-analysis of clinical trials for the most studied agents to estimate mean weight loss: metformin (2.93 kg, 95% C.I. 0.97-4.89, p=0.003), H2 antagonists (1.78 kg (95% C.I. -0.50-4.06, p=0.13), topiramate (3.95 kg 95% C.I. 1.77-6.12, p=0.0004), and norepinephrine reuptake inhibitors (1.30 kg (95% C.I. -0.06-2.66, p=0.06). Among the studied options for antipsychotic-related weight gain, metformin has the strongest evidence base and may improve vascular risk factors beyond obesity. The use of topiramate is also supported by the literature and may improve psychotic symptoms in those refractory to treatment. A marginal benefit is seen with norepinephrine reuptake inhibitors, and any vascular benefits from such weight loss may be counteracted by increases in blood pressure or heart rate. Pharmacological therapies may offer benefits as a means of supplementing the effects of lifestyle changes for weight loss. However, the existing evidence provides little evidence of specificity for pharmacological therapies to antipsychotic-induced weight gain and has not demonstrated any improvement in vascular outcomes.

Keywords: Antipsychotic agents, Schizophrenia, Bipolar Disorder, Dyslipidemias, Major Depression, Meta-analysis, Obesity, Psychotic Disorders, Vascular Diseases, Weight Loss


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy